Limits...
A highlight from the LUPUS 2014 meeting: eight great ideas.

Buyon JP, Cohen P, Merrill JT, Gilkeson G, Kaplan M, James J, McCune WJ, Bernatsky S, Elkon K - Lupus Sci Med (2015)

Bottom Line: This review describes eight 'great ideas' regarding bench-to-bedside considerations in systemic lupus erythematosus (SLE) presented at the second international LUPUS meeting in Quebec, September 2014.The topics included: correcting the impaired clearance of apoptotic fragments; optimisation of clinical trial design: the PERFECT (Pre Evaluation Reducing Frighteningly Elevated Coverable Targets) study; lipidomics and metabolomics in SLE; importance of the inflammasome; identification and treatment of asymptomatic autoimmunity: prevention of SLE; combining low doses of hydroxychloroquine and quinacrine for long-term maintenance therapy of SLE; reducing emergency room visits and the critical relevance of the autoantigen.

View Article: PubMed Central - PubMed

Affiliation: Division of Rheumatology, Department of Medicine , NYU School of Medicine , New York, New York , USA.

ABSTRACT
This review describes eight 'great ideas' regarding bench-to-bedside considerations in systemic lupus erythematosus (SLE) presented at the second international LUPUS meeting in Quebec, September 2014. The topics included: correcting the impaired clearance of apoptotic fragments; optimisation of clinical trial design: the PERFECT (Pre Evaluation Reducing Frighteningly Elevated Coverable Targets) study; lipidomics and metabolomics in SLE; importance of the inflammasome; identification and treatment of asymptomatic autoimmunity: prevention of SLE; combining low doses of hydroxychloroquine and quinacrine for long-term maintenance therapy of SLE; reducing emergency room visits and the critical relevance of the autoantigen.

No MeSH data available.


Related in: MedlinePlus

Proposed working model of SLE pathogenesis and progression from clinically asymptomatic to overt disease.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4493165&req=5

LUPUS2015000087F3: Proposed working model of SLE pathogenesis and progression from clinically asymptomatic to overt disease.

Mentions: Recent and ongoing studies suggest that immune dysregulation begins well before SLE is clinically apparent. In one model of SLE pathogenesis, in genetically predisposed individuals, select environmental triggers stimulate autoantibody production, initiating a period of benign autoimmunity (figure 3). Some individuals remain in this period of benign autoimmunity indefinitely, while others transition to pathogenic autoimmunity. This suggests that after the appearance of autoantibodies, a secondary insult such as inappropriate inflammatory cytokine production leads to increased autoantibody formation and further activation of T and B lymphocytes. With these developments, the patient enters a period of preclinical pathogenic immunity. As antibody targets diversify, cytokine production increases and tissue damage accumulates, the early signs of SLE become clinically apparent. The patient finally meets the criteria for SLE classification, after irreversible damage has occurred and well after the onset of pathogenic autoimmunity.


A highlight from the LUPUS 2014 meeting: eight great ideas.

Buyon JP, Cohen P, Merrill JT, Gilkeson G, Kaplan M, James J, McCune WJ, Bernatsky S, Elkon K - Lupus Sci Med (2015)

Proposed working model of SLE pathogenesis and progression from clinically asymptomatic to overt disease.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4493165&req=5

LUPUS2015000087F3: Proposed working model of SLE pathogenesis and progression from clinically asymptomatic to overt disease.
Mentions: Recent and ongoing studies suggest that immune dysregulation begins well before SLE is clinically apparent. In one model of SLE pathogenesis, in genetically predisposed individuals, select environmental triggers stimulate autoantibody production, initiating a period of benign autoimmunity (figure 3). Some individuals remain in this period of benign autoimmunity indefinitely, while others transition to pathogenic autoimmunity. This suggests that after the appearance of autoantibodies, a secondary insult such as inappropriate inflammatory cytokine production leads to increased autoantibody formation and further activation of T and B lymphocytes. With these developments, the patient enters a period of preclinical pathogenic immunity. As antibody targets diversify, cytokine production increases and tissue damage accumulates, the early signs of SLE become clinically apparent. The patient finally meets the criteria for SLE classification, after irreversible damage has occurred and well after the onset of pathogenic autoimmunity.

Bottom Line: This review describes eight 'great ideas' regarding bench-to-bedside considerations in systemic lupus erythematosus (SLE) presented at the second international LUPUS meeting in Quebec, September 2014.The topics included: correcting the impaired clearance of apoptotic fragments; optimisation of clinical trial design: the PERFECT (Pre Evaluation Reducing Frighteningly Elevated Coverable Targets) study; lipidomics and metabolomics in SLE; importance of the inflammasome; identification and treatment of asymptomatic autoimmunity: prevention of SLE; combining low doses of hydroxychloroquine and quinacrine for long-term maintenance therapy of SLE; reducing emergency room visits and the critical relevance of the autoantigen.

View Article: PubMed Central - PubMed

Affiliation: Division of Rheumatology, Department of Medicine , NYU School of Medicine , New York, New York , USA.

ABSTRACT
This review describes eight 'great ideas' regarding bench-to-bedside considerations in systemic lupus erythematosus (SLE) presented at the second international LUPUS meeting in Quebec, September 2014. The topics included: correcting the impaired clearance of apoptotic fragments; optimisation of clinical trial design: the PERFECT (Pre Evaluation Reducing Frighteningly Elevated Coverable Targets) study; lipidomics and metabolomics in SLE; importance of the inflammasome; identification and treatment of asymptomatic autoimmunity: prevention of SLE; combining low doses of hydroxychloroquine and quinacrine for long-term maintenance therapy of SLE; reducing emergency room visits and the critical relevance of the autoantigen.

No MeSH data available.


Related in: MedlinePlus